Therapeutic potential and molecular mechanism of a novel sulfonamide anticancer drug, indisulam (E7070) in combination with CPT-11 for cancer treatment

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 5, 2012, Pages 1353-1362

  Ozawa, Yoichi ^a   Kusano, Kazutomi ^a   Owa, Takashi ^b   Yokoi, Akira ^a   Asada, Makoto ^a   Yoshimatsu, Kentaro ^a  

^a EISAI CO LTD   (Japan)

^b EISAI INC   (United States)

Author keywords

Indisulam; Isobologram analysis; SN 38; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); FIRTECAN; INDISULAM; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA BINDING PROTEIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE II ALPHA; DRUG DERIVATIVE; N (3 CHLORO 7 INDOLYL) 1,4 BENZENEDISULPHONAMIDE; N-(3-CHLORO-7-INDOLYL)-1,4-BENZENEDISULPHONAMIDE; SULFONAMIDE; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL COUNT; CHEMOSENSITIVITY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TUMOR LEVEL; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ANIMAL; COLORECTAL TUMOR; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; FEMALE; GENETICS; METABOLISM; MICROARRAY ANALYSIS; NUDE MOUSE; PATHOLOGY; TIME; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CAMPTOTHECIN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICE, NUDE; MICROARRAY ANALYSIS; SULFONAMIDES; TIME FACTORS; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862296019     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1844-8     Document Type: Article

References (37)

1. Owa T, Yoshino H, Okauchi T et al (1999) Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J Med Chem 42:3789-3799 (Pubitemid 29453460)
2. Owa T, Yoshino H, Okauchi T et al (2002) Synthesis and biological evaluation of N-(7-indolyl)-3-pyridinesulfonamide derivatives as potent antitumor agents. Bioorg Med Chem Lett 12:2097-2100 (Pubitemid 34804374)
3. Supuran CT (2003) Indisulam: an anticancer sulfonamide in clinical development. Expert Opin Investig Drugs 12:283-287 (Pubitemid 36204606)
4. Haddad RI, Weinstein LJ, Wieczorek TJ et al (2004) A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor. Clin Cancer Res 10:4680-4687 (Pubitemid 38955518)
5. Smyth JF, Aamdal S, Awada A et al (2005) Phase II study of E7070 in patients with metastatic melanoma. Ann Oncol 16: 158-161 (Pubitemid 40124494)
6. Talbot DC, von Pawel J, Cattell E et al (2007) A randomized phase II pharmacokinetic and pharmacodynamics study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer. Clin Cancer Res 13:1816-1822 (Pubitemid 46952951)
7. Ozawa Y, Sugi NH, Nagasu T et al (2001) E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. Eur J Cancer 37:2275-2282 (Pubitemid 33001300)
8. Owa T, Ozawa Y, Yokoi A et al (2004) Identification of response marker genes of the antitumor sulfonamide indisulam (E7070). Eur J Cancer 2(8):128
9. Tsuruo T, Matsuzaki T, Matsushita M et al (1988) Antitumor eVect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 21:71-74 (Pubitemid 18050487)
10. Weekes J, Lam AK, Sebesan S et al (2009) Irinotecan therapy and molecular targets in colorectal cancer: a systemic review. World J Gastroenterol 15:3597-3602
11. Kim R, Hirabayashi N, Nishiyama M et al (1992) Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer 50: 760-766
12. Whitacre CM, Zborowska E, Gordon NH et al (1997) Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer Res 57:1425-1428 (Pubitemid 27175554)
13. Sugimoto Y, Tsukahara S, Oh-hara T et al (1990) Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res 50:7962-7965
14. Eng WK, McCabe FL, Tan KB et al (1990) Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol 38:471-480 (Pubitemid 20356196)
15. Woessner RD, Eng WK, Hofmann GA et al (1992) Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Oncol Res 4:481-488 (Pubitemid 23179059)
16. Slinker BK (1998) The statistics of synergism. J Mol Cell Cardiol 30:723-731 (Pubitemid 28190716)
17. Kano Y, Akutsu M, Tsunoda S et al (2000) In vitro cytotoxic eVects of Xudarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis. Leukemia 14:379-388 (Pubitemid 30142859)
18. Steel GG, Peckham MJ (1979) Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5:85-91 (Pubitemid 9120186)
19. Ferguson PJ, Fisher MH, Stephenson J et al (1988) Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res 48:5956-5964 (Pubitemid 18266783)
20. Lefevre D, Riou JF, Ahomadegbe JC et al (1991) Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line. Decrease of topoisomerase II and increase of both topoisomerase I and acidic glutathione S transferase. Biochem Pharmacol 41:1967-1979
21. Riou JF, Grondard L, Petitgenet O et al (1993) Altered topoisomerase I activity and recombination activating gene expression in a human leukemia cell line resistant to doxorubicin. Biochem Pharmacol 46:851-861 (Pubitemid 23272766)
22. Wang JC (1985) DNA topoisomerases. Annu Rev Biochem 54:665-697 (Pubitemid 15073661)
23. Oda Y, Owa T, Sato T et al (2003) Quantitative chemical proteomics for identifying candidate drug targets. Anal Chem 75: 2159-2165 (Pubitemid 36542358)
24. Kim HD, Tomida A, Ogiso Y, Tsuruo T (1999) Glucose-regulated stresses cause degradation of DNA topoisomerase IIalpha by inducing nuclear proteasome during G1 cell cycle arrest in cancer cells. J Cell Physiol 180:97-104 (Pubitemid 29249717)
25. Yun J, Tomida A, Andoh T, Tsuruo T (2004) Interaction between glucose-regulated destruction domain of DNA topoisomerase IIalpha and MPN domain of Jab1/CSN5. J Biol Chem 279:31296-31303 (Pubitemid 39037795)
26. Kimura T, Kudoh S, Hirata K (2011) Review of the management of relapsed small-cell lung cancer with amrubicin hydrochloride. Clin Med Insights Oncol 5:23-34
27. D'Arpa P, Liu LF (1989) Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 989:163-177 (Pubitemid 20008970)
28. Kimura T (2001) In vitro schedule dependency in the treatment of topoisomerase I and II inhibitor. Osaka City Med J 47:33-41
29. Kaufmann SH (1991) Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 51:1129-1136
30. Furue H (1999) Combination chemotherapy-present status and problems. Gan To Kagaku Ryoho 26:589-596
31. Rothenberg ML, Kuhn JG, Burris HA III et al (1993) Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194-2204
32. Terret C, Zanetta S, Roché H et al (2003) Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG). Eur J Cancer 39:1097-1104 (Pubitemid 36555867)
33. Dittrich C, Dumez H, Calvert H et al (2003) Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors. Clin Cancer Res 9:5195-5204 (Pubitemid 37413569)
34. Raymond E, ten Bokkel Huinink WW, Taïeb J et al (2002) Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer. J Clin Oncol 20:3508-3521
35. Hammond LA, Eckardt JR, Ganapathi R, Burris HA, Rodriguez GA, Eckhardt SG et al (1998) A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide. Clin Cancer Res 4:1459-1467 (Pubitemid 28265229)
36. Rubin E, Wood V, Bharti A, Trites D, Lynch C, Hurwitz S et al (1995) A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin Cancer Res 1:269-276
37. Licitra EJ, Vyas V, Nelson K, Musanti R, Beers S, Thomas C et al (2003) Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy. Clin Cancer Res 9:1673-1679 (Pubitemid 36554590)